News

Pfizer said that Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3. Pfizer Oncology Business Unit Clinical Development senior

Of the additional sites, the Stanford Cancer Center (Stanford, California) under principal investigator Jason Gotlib, has already commenced enrolling patients, additionally the company will start recruiting patients in

Ziopharm said that the preclinical work was designed to study darinaparsin’s cytotoxic and radiosensitizing effects against different solid tumor cell lines under both normoxic (NO) and hypoxic (HO)

J&J and Takeda, which co-market Velcade, said the impurities were made of a white polyester like material that stemmed from a filtration system used in the manufacturing process.

Elorac said that in two phase III pivotal double-blind, randomised, vehicle-controlled, paired-comparison, multi-center studies, the results showed reductions in acne lesion counts after 8 and 12 weeks of

Researchers at Marina Biotech have identified new DiLA2-based formulations composed of multiple DiLA2 molecules, that when paired with a UsiRNA targeting FVII mRNA in liver (hepatocytes) of mice,

Synthon has also completed registration procedures for Tamsulosin, reported PharmaLive.com. Tamsulosin, an a1a-selective alpha blocker, contains the active ingredient Tamsulosin hydrochloride. Developed by Yamanouchi Pharmaceuticals (now part of

In exchange for the technology, BioSante received a 19.9% ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and

The updated data showed that the median time to progression for patients receiving Zybrestat plus bevacizumab and chemotherapy was 9.5 months, compared with a median time to progression